- David S. Ettinger, MD,
- Douglas E. Wood, MD, FRCSEd,
- Dara L. Aisner, MD, PhD,
- Wallace Akerley, MD,
- Jessica Bauman, MD,
- Lucian R. Chirieac, MD,
- Thomas A. D’Amico, MD,
- Malcolm M. DeCamp, MD,
- Thomas J. Dilling, MD, MS,
- Michael Dobelbower, MD, PhD,
- Robert C. Doebele, MD, PhD,
- Ramaswamy Govindan, MD,
- Matthew A. Gubens, MD, MS,
- Mark Hennon, MD,
- Leora Horn, MD, MSc, FRCPC,
- Ritsuko Komaki, MD,
- Rudy P. Lackner, MD,
- Michael Lanuti, MD,
- Ticiana A. Leal, MD,
- Leah J. Leisch, MD,
- Rogerio Lilenbaum, MD,
- Jules Lin, MD,
- Billy W. Loo Jr, MD, PhD,
- Renato Martins, MD, MPH,
- Gregory A. Otterson, MD,
- Karen Reckamp, MD, MS,
- Gregory J. Riely, MD, PhD,
- Steven E. Schild, MD,
- Theresa A. Shapiro, MD, PhD,
- James Stevenson, MD,
- Scott J. Swanson, MD,
- Kurt Tauer, MD,
- Stephen C. Yang, MD,
- Kristina Gregory, RN, MSN, OCN and
- Miranda Hughes, PhD
Abstract
This selection from the NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) focuses on targeted therapies and immunotherapies for metastatic NSCLC, because therapeutic recommendations are rapidly changing for metastatic disease. For example, new recommendations were added for atezolizumab, ceritinib, osimertinib, and pembrolizumab for the 2017 updates.
Footnotes
-
Please Note
The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way.
© National Comprehensive Cancer Network, Inc. 2017, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.
-
Disclosures for the Non–Small Cell Lung Cancer Panel
At the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.
Individual disclosures for the NCCN Non–Small Cell Lung Cancer Panel members can be found on page 535. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)
These guidelines are also available on the Internet. For the latest update, visit NCCN.org.
-
NCCN Non–Small Cell Lung Cancer Panel Members
*David S. Ettinger, MD/Chair†
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
*Douglas E. Wood, MD, FRCSEd/Vice Chair¶
Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance
Dara L. Aisner, MD, PhD≠
University of Colorado Cancer Center
Wallace Akerley, MD†
Huntsman Cancer Institute at the University of Utah
Jessica Bauman, MD‡
Fox Chase Cancer Center
Lucian R. Chirieac, MD≠
Dana-Farber/Brigham and Women’s Cancer Center
Thomas A. D’Amico, MD¶
Duke Cancer Institute
Malcolm M. DeCamp, MD¶
Robert H. Lurie Comprehensive Cancer Center of Northwestern University
Thomas J. Dilling, MD, MS§
Moffitt Cancer Center
Michael Dobelbower, MD, PhD§
University of Alabama at Birmingham Comprehensive Cancer Center
Robert C. Doebele, MD, PhD†
University of Colorado Cancer Center
Ramaswamy Govindan, MD†
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
Matthew A. Gubens, MD, MS†
UCSF Helen Diller Family Comprehensive Cancer Center
Mark Hennon, MD¶
Roswell Park Cancer Institute
Leora Horn, MD, MSc, FRCPC†
Vanderbilt-Ingram Cancer Center
Ritsuko Komaki, MD§
The University of Texas MD Anderson Cancer Center
Rudy P. Lackner, MD¶
Fred & Pamela Buffett Cancer Center
Michael Lanuti, MD¶
Massachusetts General Hospital Cancer Center
Ticiana A. Leal, MD†
University of Wisconsin Carbone Cancer Center
Leah J. Leisch, MDÞ
University of Alabama at Birmingham Comprehensive Cancer Center
Rogerio Lilenbaum, MD†
Yale Cancer Center/Smilow Cancer Hospital
Jules Lin, MD¶
University of Michigan Comprehensive Cancer Center
Billy W. Loo Jr, MD, PhD§
Stanford Cancer Institute
Renato Martins, MD, MPH†
Fred Hutchinson Cancer Research Center/Seattle Cancer Care
Alliance Gregory A. Otterson, MD†
The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute
Karen Reckamp, MD, MS†‡
City of Hope Comprehensive Cancer Center
Gregory J. Riely, MD, PhD†Þ
Memorial Sloan Kettering Cancer Center
Steven E. Schild, MD§
Mayo Clinic Cancer Center
Theresa A. Shapiro, MD, PhD¥
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
James Stevenson, MD†
Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute
Scott J. Swanson, MD¶
Dana-Farber/Brigham and Women’s Cancer Center
Kurt Tauer, MD†
St. Jude Children’s Research Hospital/University of Tennessee Health Science Center
Stephen C. Yang, MD¶
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCCN Staff: Kristina Gregory, RN, MSN, OCN, and Miranda Hughes, PhD
KEY:
*Discussion Section Writing Committee
Specialties: †Medical Oncology; ¶Surgery/Surgical Oncology; §Radiation Oncology/Radiotherapy; ≠Pathology; ‡Hematology/Hematology Oncology; фDiagnostic/Interventional Radiology; ¥Patient Advocate; ÞInternal Medicine
- Copyright © 2017 by the National Comprehensive Cancer Network
